Rupert Bartsch, MD, discusses findings from the final analysis of the phase 2 TUXEDO-1 trial of trastuzumab deruxtecan in patients with HER2-positive breast cancer with active brain metastases.
MELBOURNE, Australia, Sept. 6, 2023 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)today announces presentations featuring the Company's theranostic programs at the 36th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Vienna from 9 - 13 September 2023. Further data from Telix's completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118) will be presented in on oral session on Sunday 10 September. In addition, the congress program features the following Telix initiatives: Sponsored symposium on personalised diagnostics in urological cancers: the promise of nuclear medicine; Phase III ProstACT GLOBAL study of TLX591 investigational prostate cancer therapy; Artificial intelligence (AI) Segmentation and primary characterisation of prostate cancer lesions using models trained on 68Ga-PSMA-11 image datasets; Nobody
Fragments of a skull believed to have been that of composer Ludwig van Beethoven have been donated to a university in Austria after spending decades in the United States.
OAK BROOK, Ill. – A new neuroimaging technique can detect biochemical changes in the brains of people with multiple sclerosis (MS) early in the course of the disease, paving the way for faster.